Therapy News and Research

RSS

Ono, Bristol-Myers Squibb partner to develop BMS-936558/ONO-4538 and ORENCIA

Bristol-Myers Squibb Company and Ono Pharmaceutical Co., Ltd., today announced an agreement to expand Bristol-Myers Squibb's territorial rights to develop and commercialize the anti-PD-1 antibody known as BMS-936558/ONO-4538, and to create a strategic alliance for the co-development and co-commercialization of ORENCIA in Japan.

21 Sep 2011

Impotence after prostate cancer treatment

According to researchers patients undergoing treatment for prostate cancer could be at a risk of impotence. According to the new study, published in the Journal of the American Medical Association there may be a formula to help gauge those risks for three common types of treatment, including surgery and radiation.

21 Sep 2011

Prediction models may effectively identify erectile function after prostate cancer surgery

The development of prediction models that included variables such as pretreatment sexual function, patient characteristics and treatment factors appear to be effective at predicting erectile function 2 years after prostatectomy, external radiotherapy, or brachytherapy for prostate cancer, according to a study in the September 21 issue of JAMA.

21 Sep 2011

UAB surgeons perform second toe-to-thumb transplant

Cary Ramey has the word Carpe tattooed on the underside of his right wrist and Diem tattooed on the left. He loves extreme sports, especially mountain biking and "rock climbing without the ropes."

21 Sep 2011

Matrix receives FDA's tentative approval for novel co-packaged version of HIV/AIDS therapy

Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) through the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Lamivudine / Tenofovir Disoproxil Fumarate Tablets, 300 mg/300 mg, co-packaged with Nevirapine Tablets, 200 mg.

21 Sep 2011

Silence Therapeutics reports revenue of £354,078 for six months ended 30 June 2011

Silence Therapeutics Plc, a leading international RNAi therapeutics company, today provides a corporate update and announces its interim results for the six months ended 30 June 2011.

21 Sep 2011

UIC wins HRSA-MCHB grant to expand disabilities training program

A successful University of Illinois at Chicago-based interdisciplinary effort to train leaders in programs that help children with developmental disabilities and autism has won a $3.3 million five-year grant from the Department of Health and Human Services' Health Resources and Services Administration-Maternal and Child Health Bureau.

21 Sep 2011

Tips for parents to keep their family physically fit and healthy

Pick up any newspaper, magazine or online publication and news about obesity is everywhere. While some parents feel helpless in the fight to keep their family physically fit and healthy, other parents are taking action. Studies show that exercising as a family not only promotes good health but also helps strengthen the emotional bonds between family members.

21 Sep 2011

Beta-blocker drugs may improve survival time for melanoma patients

Beta-blocker drugs, commonly used to treat high blood pressure, may also play a major role in slowing the progression of certain serious cancers, based on a new study.

21 Sep 2011

Niiki Pharma announces positive data from ongoing trial of novel anti-cancer agent NKP-1339

Niiki Pharma Inc. announced interim results from the ongoing Phase I clinical trial of its lead product, NKP-1339. NKP-1339 is a first-in-class transferrin targeted small molecule that down-regulates GRP78, a key regulator of mis-folded protein processing and a tumor survival factor.

20 Sep 2011

Multimodal analgesia important for effective control of pain

Efforts to effectively control pain in hospitalized patients with opioid (narcotic) analgesics can lead to unintentional sedation and respiratory depression, which are serious adverse events affecting the quality of recovery for patients.

20 Sep 2011

Water plays a decisive role in biologically active enzyme substrate compounds

In biologically active enzyme substrate compounds, as can be found in medicines, water plays a more decisive role than has been imagined up to now. The surrounding water acts like an "adhesive", in order to keep the substrate at the right place on an enzyme.

20 Sep 2011

New research has potential to alleviate side effects of cancer treatments

Beth Faiman MSN, CNP, a doctoral candidate at the Frances Payne Bolton School of Nursing at Case Western Reserve University, is studying whether an over-the-counter medication could ease chemotherapy side effects for people with blood and bone marrow cancers.

20 Sep 2011

Tokai raises $23M in Series D3 financing

Tokai Pharmaceuticals, a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that it has raised $23 million in a Series D3 financing.

20 Sep 2011

Autism Speaks and Doug Flutie, Jr. Foundation select apps to help people with ASD

Autism Speaks, the world's largest autism science and advocacy organization, and the Doug Flutie Jr. Foundation for Autism today announced technology applications ("apps") to be developed to benefit people with autism as part of the "Hacking Autism" initiative.

20 Sep 2011

Cardiff develops simple and effective wound test that could save NHS millions

Scientists in Cardiff are developing a simple but effective test to predict whether chronic wounds will respond to conventional treatment - which could save the NHS tens of millions of pounds annually.

20 Sep 2011

WHO, WEF reports examine cost of treating and preventing, economic burden of NCDs

Low-income countries "could introduce measures to prevent and treat millions of cases of cancer, heart disease, diabetes and lung disease for a little as $1.20 per person per year, the World Health Organization (WHO) said on Sunday" in a report released on the eve of the U.N. High-level Meeting on Non-Communicable Diseases (NCDs) taking place this week in New York, Reuters reports.

20 Sep 2011

BIOTRONIK completes enrollment in Passeo-18 Lux DEB catheter clinical study for PAD

BIOTRONIK, a leading European manufacturer of therapy solutions for vascular intervention, announced the completion of enrollment in the BIOLUX P-I - a clinical study investigating the use of a drug-eluting balloon (DEB) catheter, a promising new approach to treating disease in the more challenging peripheral vascular anatomy.

20 Sep 2011

NYU Langone creates new Joan H. Tisch Center for Women's Health in New York City

NYU Langone Medical Center announced the establishment of its new Joan H. Tisch Center for Women's Health on the Upper East Side of Manhattan in New York City.

20 Sep 2011

FoxM1 protein plays a critical role in development of medulloblastomas

Medulloblastomas constitute the most frequent class of malignant childhood brain tumor. Tumors of this type arise due to the uncontrolled proliferation of immature nerve cells in the developing brain, and there is no targeted treatment available.

20 Sep 2011

Therapy News and Research

Ono, Bristol-Myers Squibb partner to develop BMS-936558/ONO-4538 and ORENCIA

Impotence after prostate cancer treatment

Prediction models may effectively identify erectile function after prostate cancer surgery

UAB surgeons perform second toe-to-thumb transplant

Matrix receives FDA's tentative approval for novel co-packaged version of HIV/AIDS therapy

Silence Therapeutics reports revenue of £354,078 for six months ended 30 June 2011

UIC wins HRSA-MCHB grant to expand disabilities training program

Tips for parents to keep their family physically fit and healthy

Beta-blocker drugs may improve survival time for melanoma patients

Niiki Pharma announces positive data from ongoing trial of novel anti-cancer agent NKP-1339

Multimodal analgesia important for effective control of pain

Water plays a decisive role in biologically active enzyme substrate compounds

New research has potential to alleviate side effects of cancer treatments

Tokai raises $23M in Series D3 financing

Autism Speaks and Doug Flutie, Jr. Foundation select apps to help people with ASD

Cardiff develops simple and effective wound test that could save NHS millions

WHO, WEF reports examine cost of treating and preventing, economic burden of NCDs

BIOTRONIK completes enrollment in Passeo-18 Lux DEB catheter clinical study for PAD

NYU Langone creates new Joan H. Tisch Center for Women's Health in New York City

FoxM1 protein plays a critical role in development of medulloblastomas

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News